IP Library › Granted Patent US 9,993,389
Granted Patent B2
US 9,993,389 · App. 14/122,847 · Granted Jun 12, 2018

Red blood cell products and the storage of red blood cells in containers free of phthalate plasticizer

Inventors: Katherine Radwanski (Des Plaines, IL); Craig L. Sandford (Buffalo Grove, IL); Kyungyoon Min (Kildeer, IL); Daniel Lynn (Spring Grove, IL); Tat Mui (Chicago, IL)
Assignee: FENWAL, INC.
A61J1/10A01N1/0226A01N1/0263A61K35/18A61K45/06B32B27/08B32B27/304B32B27/32A61J1/1468B32B2270/00B32B2307/7244B32B2439/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,993,389
App. No.
14/122,847
Granted
Jun 12, 2018
Kind
B2
Abstract

Red blood cell products and compositions are disclosed. The product includes a container made from PVC or a non-PVC material that is substantially free of a phthalate plasticizer but otherwise includes one or more non-phthalate plasticizers or extractable agents. The product includes a RBC concentrate which has been combined with an additive solution for storing the RBCs.

Claims (13)

1. A container for storing red blood cell compositions comprising:

one or more container walls defining an interior chamber, said container wall(s) comprising a polymeric material that includes polyvinyl chloride and that is (a) at least substantially free of phthalate and (b) comprises up to approximately 45%, by weight, of two extractable non-phthalate ester plasticizers that are effective in suppressing hemolysis in red blood cells, wherein one of said plasticizers is a citrate ester and the other of said ester plasticizers is 1, 2-cyclohexane dicarboxylic acid diisononyl ester.

2. The container of claim 1 wherein said citrate ester is n-butyryl-tri-n-hexyl-citrate.

3. The container of claim 1 wherein said citrate ester is acetyltri-n-butyl citrate.

4. The container of claim 1 further comprising at least a third agent.

5. The container of claim 4 wherein said third agent is effective in suppressing hemolysis in red blood cells.

6. The container of claim 1 wherein said citrate and 1, 2-cyclohexane dicarboxylic acid diisononyl esters together comprise between 20%-45%, by weight, of said polymeric material.

7. The container of claim 1 wherein one of said citrate and 1, 2-cyclohexane dicarboxylic acid diisononyl esters together comprises between approximately 5%-60%, by weight, of the combined weight of said citrate and 1, 2-cyclohexane dicarboxylic acid diisononyl ester and, optionally, additional agents.

8. The container of claim 1 wherein said polyvinyl chloride comprises at least approximately 55%, by weight, of said polymeric material.

9. The container of claim 1 wherein said polymeric material comprises approximately 60%-70% polyvinyl chloride, approximately 15%-30% 1, 2-cyclohexane dicarboxylic acid diisononyl ester and approximately 5%-15% citrate ester.

10. The container of claim 9 further comprising approximately 4%-10% epoxidized oil.

11. The container of claim 10 further comprising approximately 0.5%-3.0% of additional co-stabilizers and lubricants.

12. The container of claim 9 wherein said citrate ester is n-butyryl-tri-n-hexyl-citrate.

Continuity (5)
Provisional Application 61536370 · Sep 19, 2011
Provisional Application 61549562 · Oct 20, 2011
Provisional Application 61566409 · Dec 2, 2011
Provisional Application 61595891 · Feb 7, 2012
Related Publication 20140091047A1 · Apr 3, 2014